Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fesoterodine flexible dose in vulnerable elderly with OAB
NCT00928070Phase 4Completed
- Sponsor
- Pfizer
- Start
- Sep 2009
- Primary completion
- Sep 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in overactive bladder (OAB) comparing Fesoterodine with Placebo (2 arms). Primary endpoint: Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Week 12. Started Sep 2009; status: completed.
02
Drugs
fesoterodine
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT00928070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00928070.